Nitrofurantoin

Last updated

Nitrofurantoin
Nitrofurantoin.svg
Nitrofurantoin-from-xtal-3D-bs-17.png
Clinical data
Trade names Macrobid, Macrodantin, Macpac, others [1]
AHFS/Drugs.com Monograph
MedlinePlus a682291
License data
Pregnancy
category
  • AU:A
Routes of
administration 		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability 40%
Metabolism Liver (75%)
Elimination half-life 20 minutes
Excretion Kidney and bile duct
Identifiers
  • (E)-1-[(5-nitro-2-furyl)methylideneamino]imidazolidine-2,4-dione
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.000.587 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C8H6N4O5
Molar mass 238.159 g·mol−1
3D model (JSmol)
Melting point 270 to 272 °C (518 to 522 °F) (decomp.)
  • O=[N+]([O-])c2oc(/C=N/N1C(=O)NC(=O)C1)cc2
  • InChI=1S/C8H6N4O5/c13-6-4-11(8(14)10-6)9-3-5-1-2-7(17-5)12(15)16/h1-3H,4H2,(H,10,13,14)/b9-3+ Yes check.svgY
  • Key:NXFQHRVNIOXGAQ-YCRREMRBSA-N Yes check.svgY
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Nitrofurantoin is an antibacterial medication of the nitrofuran class used to treat urinary tract infections, although it is not as effective for kidney infections. [2] It is taken by mouth. [2]

Contents

Common side effects include nausea, loss of appetite, diarrhea, and headaches. [2] Rarely numbness, lung problems, or liver problems may occur. [2] It should not be used in people with kidney problems. [2] While it appears to be generally safe during pregnancy it should not be used near delivery. [2] [3] While it usually works by slowing bacterial growth, it may result in bacterial death at the high concentrations found in urine. [2]

Nitrofurantoin was first sold in 1953. [4] It is on the World Health Organization's List of Essential Medicines. [5] It is available as a generic medication. [2] In 2021, it was the 135th most commonly prescribed medication in the United States, with more than 4 million prescriptions. [6] [7]

Medical uses

100 mg Macrobid, Canada Macrobid2016.jpg
100 mg Macrobid, Canada

Uses include the treatment of uncomplicated urinary tract infections (UTIs) and prophylaxis against UTIs in people prone to recurrent UTIs. [8]

Increasing bacterial antibiotic resistance to other commonly used agents, such as trimethoprim/sulfamethoxazole and fluoroquinolones, has led to increased interest in using nitrofurantoin. [9] [10] The efficacy of nitrofurantoin in treating UTIs combined with a low rate of bacterial resistance to this agent makes it one of the first-line agents for treating uncomplicated UTIs as recommended by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. [11]

Nitrofurantoin is not recommended for the treatment of pyelonephritis, [11] and intra-abdominal abscess, [12] because of extremely poor tissue penetration and low blood levels.

Antibacterial activity

Nitrofurantoin has been shown to have good activity against:[ citation needed ]

It is used in the treatment of infections caused by these organisms. [13]

Many or all strains of the following genera are resistant to nitrofurantoin: [13]

Special populations

Pregnancy

Nitrofurantoin is pregnancy category A in Australia. [14] It is one of the few drugs commonly used in pregnancy to treat UTIs. [15] It however should not be used in late pregnancy due to the potential risk of hemolytic anemia in the newborn. [14] Newborns of women given this drug late in pregnancy had a higher risk of developing neonatal jaundice. [16]

Evidence of safety in early pregnancy is mixed as of 2017. [17] The American College of Obstetricians and Gynecologists states that while they can be used in the first trimester other options may be preferred. [17] They remain a first line treatment in the second trimester. [17] A 2015 meta analysis found no increased risk from first trimester use in cohort studies that was a slight increase of malformations in case control studies. [18]

Available forms

There are two formulations of nitrofurantoin:

Contraindications

Nitrofurantoin is contraindicated in patients with decreased renal function (CrCl < 60 ml/min) due to systemic accumulation and subtherapeutic levels reached in the urinary tract. [8] However, a retrospective chart review suggests the data for this cutoff are slim and a cutoff of CrCl < 40 ml/min would be more appropriate. [22] Many of the severe side effects of this drug are more common in the elderly and those with renal impairment, as this causes the drug to be retained in the body and reach higher systemic levels. Thus, the drug is not recommended for the elderly population according to 2012 AGS Beers Criteria. [23]

Nitrofurantoin is also contraindicated in babies up to the age of one month, as they have immature enzyme systems in their red blood cells (glutathione instability), so nitrofurantoin must not be used because it can cause haemolytic anaemia. For the same reason, nitrofurantoin should not be given to pregnant women after 38 weeks of pregnancy. Nitrofurantoin is contraindicated in patients with glucose-6-phosphate dehydrogenase deficiency (G6PD) because of risk of intravascular hemolysis resulting in anemia. [8]

Adverse effects

The most common side effects with nitrofurantoin are nausea, headache, and flatulence. Less common adverse events (occurring in less than 1% of those taking the drug) include: [8]

Lung toxicity

The pulmonary toxicity caused by nitrofurantoin can be categorized into acute, subacute, and chronic pulmonary reactions. The acute and subacute reactions are thought to be due to a hypersensitivity reaction and often resolve when the drug is discontinued. Acute reactions have been estimated to occur in about one in 5000 women who take the drug. [24] [25] These reactions usually develop 3–8 days after the first dose of nitrofurantoin, but may occur from a few hours to a few weeks after starting the drug. Symptoms include fever, dyspnea, chills, cough, pleuritic chest pain, headache, back pain, and epigastric pain. Chest radiograph will often show unilateral or bilateral infiltrates similar to pulmonary edema. Treatment includes discontinuation of the nitrofurantoin, which should result in symptom improvement within 24 hours. [26]

Chronic pulmonary reactions caused by nitrofurantoin include diffuse interstitial pneumonitis, pulmonary fibrosis, or both. [8] This uncommon reaction may occur 1 month to 6 years after starting the drug and is usually related to its total lifetime dose.[ citation needed ] This reaction manifests with progressive shortness of breath. [27] It is important to recognize nitrofurantoin as possible cause of symptoms and discontinue the drug when the suspicion of pulmonary side effects arises as it can be reversible if the drug is stopped early. [25]

Liver toxicity

Hepatic reactions, including hepatitis, cholestatic jaundice, chronic active hepatitis, and hepatic necrosis, occur rarely. The onset of chronic active hepatitis may be insidious, and patients should be monitored periodically for changes in biochemical tests that would indicate liver injury. [8] These reactions usually occur after exposure to the drug for more than 6 weeks. If signs of liver failure are observed in a patient taking nitrofurantoin, the drug should be discontinued. Re-challenge with the drug at a later date is not recommended, as the reaction may have a hypersensitivity component and recur when the drug is resumed. [28]

Neuropathy

Neuropathy is a rare side effect of taking nitrofurantoin. Patients may experience numbness and tingling in a stocking-glove pattern, which may or may not improve upon discontinuation of the drug. [29]

Pharmacology

Organisms are said to be susceptible to nitrofurantoin if their minimum inhibitory concentration is 32 μg/mL or less. The peak blood concentration of nitrofurantoin following an oral dose of nitrofurantoin 100 mg is less than 1 μg/mL and may be undetectable. Its bioavailability is about 90% and the urinary excretion is 40% [30] tissue penetration is negligible; the drug is well concentrated in the urine: 75% of the dose is rapidly metabolised by the liver, but 25% of the dose is excreted in the urine unchanged, reliably achieving levels of 200 μg/mL or more. In studies of dogs, the majority of urinary excretion is through glomerular filtration with some tubular secretion. [31] There is also tubular absorption which is increased with urine acidification. [31] However the activity of nitrofurantoin is also pH dependent and mean inhibitory concentration rises sharply with increased pH above 6. [31] Nitrofurantoin cannot be used to treat infections other than simple cystitis.

At the concentrations achieved in urine (>100 μg/mL), nitrofurantoin is a bactericide. It is bacteriostatic against most susceptible organisms at concentrations less than 32 μg/mL. [8]

Nitrofurantoin and the quinolone antibiotics are mutually antagonistic in vitro. It is not known whether this is of clinical significance, but the combination should be avoided. [8]

Resistance to nitrofurantoin may be chromosomal or plasmid-mediated and involves inhibition of nitrofuran reductase. [32] Acquired resistance in E. coli continues to be rare.

Nitrofurantoin and its metabolites are excreted mainly by the kidneys. In renal impairment, the concentration achieved in urine may be subtherapeutic. Nitrofurantoin should not be used in patients with a creatinine clearance of 60 mL/min or less. However, a retrospective chart review may suggest nitrofurantoin is not contraindicated in this population. [33]

Mechanism of action

Nitrofurantoin is concentrated in the urine, leading to higher and more effective levels in the urinary tract than in other tissues or compartments. [25] With a 100 mg oral dose, plasma levels are typically less than 1 μg/mL while in the urine it reaches 200 μg/mL. [34]

The drug works by damaging bacterial DNA, since its reduced form is highly reactive. [8] This is made possible by the rapid reduction of nitrofurantoin inside the bacterial cell by flavoproteins (nitrofuran reductase) to multiple reactive intermediates that attack ribosomal proteins, DNA, [35] respiration, pyruvate metabolism and other macromolecules within the cell. Nitrofurantoin exerts greater effects on bacterial cells than mammalian cells because bacterial cells activate the drug more rapidly. It is not known which of the actions of nitrofurantoin is primarily responsible for its bactericidal activity. The broad mechanism of action for this drug likely is responsible for the low development of resistance to its effects, as the drug affects many different processes important to the bacterial cell. [8]

History

Nitrofurantoin has been available for the treatment of lower urinary tract infections (UTIs) since 1953. [4]

Society and culture

Brand names

Nitrofurantoin is marketed under many names in countries worldwide. [36]

Animal feed

Residues from the breakdown of nitrofuran veterinary antibiotics, including nitrofurantoin, have been found in chicken in Vietnam, China, Brazil, and Thailand. [37] The European Union banned the use of nitrofurans in food producing animals by classifying it in ANNEX IV (list of pharmacologically active substances for which no maximum residue limits can be fixed) of the Council Regulation 2377/90. The Food and Drug Administration (FDA) of the United States has prohibited furaltadone since February 1985 and withdrew the approval for the other nitrofuran drugs (except some topical uses) in January 1992. The topical use of furazolidone and nitrofurazone was prohibited in 2002. Australia prohibited the use of nitrofurans in food production in 1992. Japan did not allocate MRLs for nitrofurans leading to the implementation of a "zero tolerance or no residue standard". In Thailand, the Ministry of Health issued in 2001 Proclamation No. 231 MRL of veterinary drug in food which did not allocate MRL for nitrofurans. The Ministry of Agriculture and Cooperatives had already prohibited importation and use of furazolidone and nitrofurazone in animal feed in 1999 which was extended to all nitrofurans in 2002. Several metabolites of nitrofurans, such as furazolidone, furaltadone and nitrofurazone cause cancer or genetic damage in rats. [37]

Related Research Articles

<span class="mw-page-title-main">Ciprofloxacin</span> Fluoroquinolone antibiotic

Ciprofloxacin is a fluoroquinolone antibiotic used to treat a number of bacterial infections. This includes bone and joint infections, intra-abdominal infections, certain types of infectious diarrhea, respiratory tract infections, skin infections, typhoid fever, and urinary tract infections, among others. For some infections it is used in addition to other antibiotics. It can be taken by mouth, as eye drops, as ear drops, or intravenously.

<span class="mw-page-title-main">Urinary tract infection</span> Infection that affects part of the urinary tract

A urinary tract infection (UTI) is an infection that affects a part of the urinary tract. Lower urinary tract infections may involve the bladder (cystitis) or urethra (urethritis) while upper urinary tract infections affect the kidney (pyelonephritis). Symptoms from a lower urinary tract infection include suprapubic pain, painful urination (dysuria), frequency and urgency of urination despite having an empty bladder. Symptoms of a kidney infection, on the other hand, are more systemic and include fever or flank pain usually in addition to the symptoms of a lower UTI. Rarely, the urine may appear bloody. Symptoms may be vague or non-specific at the extremities of age.

<span class="mw-page-title-main">Trimethoprim</span> Antibiotic

Trimethoprim (TMP) is an antibiotic used mainly in the treatment of bladder infections. Other uses include for middle ear infections and travelers' diarrhea. With sulfamethoxazole or dapsone it may be used for Pneumocystis pneumonia in people with HIV/AIDS. It is taken orally.

<span class="mw-page-title-main">Levofloxacin</span> Antibiotic

Levofloxacin, sold under the brand name Levaquin among others, is an antibiotic medication. It is used to treat a number of bacterial infections including acute bacterial sinusitis, pneumonia, H. pylori, urinary tract infections, Legionnaires' disease, chronic bacterial prostatitis, and some types of gastroenteritis. Along with other antibiotics it may be used to treat tuberculosis, meningitis, or pelvic inflammatory disease. Use is generally recommended only when other options are not available. It is available by mouth, intravenously, and in eye drop form.

<span class="mw-page-title-main">Ofloxacin</span> Antibiotic to treat bacterial infections

Ofloxacin is a quinolone antibiotic useful for the treatment of a number of bacterial infections. When taken by mouth or injection into a vein, these include pneumonia, cellulitis, urinary tract infections, prostatitis, plague, and certain types of infectious diarrhea. Other uses, along with other medications, include treating multidrug resistant tuberculosis. An eye drop may be used for a superficial bacterial infection of the eye and an ear drop may be used for otitis media when a hole in the ear drum is present.

<span class="mw-page-title-main">Cefixime</span> A third generation cephalosporin antibiotic

Cefixime, sold under the brand name Suprax among others, is an antibiotic medication used to treat a number of bacterial infections. These infections include otitis media, strep throat, pneumonia, urinary tract infections, gonorrhea, and Lyme disease. For gonorrhea typically only one dose is required. In the United States it is a second-line treatment to ceftriaxone for gonorrhea. It is taken by mouth.

<span class="mw-page-title-main">Pyelonephritis</span> Medical condition

Pyelonephritis is inflammation of the kidney, typically due to a bacterial infection. Symptoms most often include fever and flank tenderness. Other symptoms may include nausea, burning with urination, and frequent urination. Complications may include pus around the kidney, sepsis, or kidney failure.

<span class="mw-page-title-main">Cefaclor</span> Chemical compound

Cefaclor, sold under the trade name Ceclor among others, is a second-generation cephalosporin antibiotic used to treat certain bacterial infections such as pneumonia and infections of the ear, lung, skin, throat, and urinary tract. It is also available from other manufacturers as a generic.

<i>Staphylococcus saprophyticus</i> Species of bacterium

Staphylococcus saprophyticus is a Gram-positive coccus belonging to the genus Staphylococcus. S. saprophyticus is a common cause of community-acquired urinary tract infections.

<span class="mw-page-title-main">Tobramycin</span> Chemical compound

Tobramycin is an aminoglycoside antibiotic derived from Streptomyces tenebrarius that is used to treat various types of bacterial infections, particularly Gram-negative infections. It is especially effective against species of Pseudomonas.

<span class="mw-page-title-main">Norfloxacin</span> Chemical compound, antibiotic

Norfloxacin, sold under the brand name Noroxin among others, is an antibiotic that belongs to the class of fluoroquinolone antibiotics. It is used to treat urinary tract infections, gynecological infections, inflammation of the prostate gland, gonorrhea and bladder infection. Eye drops were approved for use in children older than one year of age.

<span class="mw-page-title-main">Nitrofuran</span> Class of pharmaceutical drugs

Nitrofurans are a class of drugs typically used as antibiotics or antimicrobials. The defining structural component is a furan ring with a nitro group.

<span class="mw-page-title-main">Cefditoren</span> Chemical to treat skin infections

Cefditoren, also known as cefditoren pivoxil is an antibiotic used to treat infections caused by Gram-positive and Gram-negative bacteria that are resistant to other antibiotics. It is mainly used for treatment of community acquired pneumonia. It is taken by mouth and is in the cephalosporin family of antibiotics, which is part of the broader beta-lactam group of antibiotics.

<span class="mw-page-title-main">Fosfomycin</span> Chemical compound

Fosfomycin, sold under the brand name Monurol among others, is an antibiotic primarily used to treat lower urinary tract infections. It is not indicated for kidney infections. Occasionally it is used for prostate infections. It is generally taken by mouth.

<span class="mw-page-title-main">Bacteriuria</span> Medical condition

Bacteriuria is the presence of bacteria in urine. Bacteriuria accompanied by symptoms is a urinary tract infection while that without is known as asymptomatic bacteriuria. Diagnosis is by urinalysis or urine culture. Escherichia coli is the most common bacterium found. People without symptoms should generally not be tested for the condition. Differential diagnosis include contamination.

<span class="mw-page-title-main">Prulifloxacin</span> Chemical compound

Prulifloxacin is an older synthetic antibiotic of the fluoroquinolone class undergoing clinical trials prior to a possible NDA submission to the U.S. Food and Drug Administration (FDA). It is a prodrug which is metabolized in the body to the active compound ulifloxacin. It was developed over two decades ago by Nippon Shinyaku Co. and was patented in Japan in 1987 and in the United States in 1989.

<span class="mw-page-title-main">Pivmecillinam</span> Chemical compound

Pivmecillinam (INN), or amdinocillin pivoxil (USAN), sold under the brand name Selexid and Pivya among others, is an orally active prodrug of mecillinam, an extended-spectrum penicillin antibiotic. Pivmecillinam is the pivaloyloxymethyl ester of mecillinam.

<span class="mw-page-title-main">Ceftolozane/tazobactam</span> Antibiotic

Ceftolozane/tazobactam, sold under the brand name Zerbaxa, is a fixed-dose combination antibiotic medication used for the treatment of complicated urinary tract infections and complicated intra-abdominal infections in adults. Ceftolozane is a cephalosporin antibiotic, developed for the treatment of infections with gram-negative bacteria that are resistant to conventional antibiotics. It was studied for urinary tract infections, intra-abdominal infections and ventilator-associated bacterial pneumonia.

<span class="mw-page-title-main">Gepotidacin</span> Chemical compound

Gepotidacin (INN) is an experimental antibiotic that acts as a topoisomerase type II inhibitor. It is being studied for the treatment of uncomplicated urinary tract infection and infection with Neisseria gonorrhoeae (gonorrhea), including multidrug resistant strains.

Meropenem/vaborbactam, sold under the brand name Vabomere among others, is a combination medication used to treat complicated urinary tract infections, complicated abdominal infections, and hospital-acquired pneumonia. It contains meropenem, a β-lactam antibiotic, and vaborbactam, a β-lactamase inhibitor. It is given by injection into a vein.

References

  1. ↑ "Nitrofurantoin".
  2. 1 2 3 4 5 6 7 8 "Nitrofurantoin". The American Society of Health-System Pharmacists. Archived from the original on 7 July 2015. Retrieved 1 August 2015.
  3. ↑ "Prescribing medicines in pregnancy database". Australian Government. 3 March 2014. Archived from the original on 8 April 2014. Retrieved 22 April 2014.
  4. 1 2 Blass B (2015). Basic Principles of Drug Discovery and Development. Elsevier. p. 511. ISBN   9780124115255. Archived from the original on 8 September 2017.
  5. ↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  6. ↑ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
  7. ↑ "Nitrofurantoin - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
  8. 1 2 3 4 5 6 7 8 9 10 "Macrobid Drug Label" (PDF). FDA. Archived (PDF) from the original on 21 April 2014. Retrieved 21 April 2014.
  9. ↑ Garau J (January 2008). "Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline". Clinical Microbiology and Infection. 14 (Suppl 1): 198–202. doi: 10.1111/j.1469-0691.2007.01852.x . PMID   18154548.
  10. ↑ McKinnell JA, Stollenwerk NS, Jung CW, Miller LG (June 2011). "Nitrofurantoin compares favorably to recommended agents as empirical treatment of uncomplicated urinary tract infections in a decision and cost analysis". Mayo Clinic Proceedings. 86 (6): 480–488. doi:10.4065/mcp.2010.0800. PMC   3104907 . PMID   21576512.
  11. 1 2 Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. (March 2011). "International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases". Clinical Infectious Diseases. 52 (5): e103–e120. doi: 10.1093/cid/ciq257 . PMID   21292654.
  12. ↑ Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, et al. (January 2010). "Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America". Clinical Infectious Diseases. 50 (2): 133–164. doi: 10.1086/649554 . PMID   20034345.
  13. 1 2 Gupta K, Scholes D, Stamm WE (February 1999). "Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women". JAMA. 281 (8): 736–738. doi: 10.1001/jama.281.8.736 . PMID   10052444.
  14. 1 2 "Nitrofurantoin Use During Pregnancy". Drugs.com. Archived from the original on 3 December 2018. Retrieved 10 September 2019.
  15. ↑ Lee M, Bozzo P, Einarson A, Koren G (June 2008). "Urinary tract infections in pregnancy". Canadian Family Physician. 54 (6): 853–854. PMC   2426978 . PMID   18556490. Archived from the original on 28 August 2021. Retrieved 4 August 2009.
  16. ↑ Nordeng H, Lupattelli A, Romøren M, Koren G (February 2013). "Neonatal outcomes after gestational exposure to nitrofurantoin". Obstetrics and Gynecology. 121 (2 Pt 1): 306–313. doi:10.1097/AOG.0b013e31827c5f88. PMID   23344280. S2CID   25848306.
  17. 1 2 3 "Sulfonamides, Nitrofurantoin, and Risk of Birth Defects - ACOG". www.acog.org. Archived from the original on 30 September 2019. Retrieved 25 November 2019.
  18. ↑ Goldberg O, Moretti M, Levy A, Koren G (February 2015). "Exposure to nitrofurantoin during early pregnancy and congenital malformations: a systematic review and meta-analysis". Journal of Obstetrics and Gynaecology Canada. 37 (2): 150–156. doi: 10.1016/S1701-2163(15)30337-6 . PMID   25767948.
  19. ↑ USFDA datahttps://www.accessdata.fda.gov/drugsatfda_docs/label/2013/016620s072lbl.pdf
  20. ↑ "Drugs for bacterial infections". Treatment Guidelines from the Medical Letter. 11 (131): 65–74. July 2013. PMID   23797768.
  21. ↑ "Nitrofurantoin Capsules - FDA prescribing information, side effects and uses". Drugs.com. Archived from the original on 1 December 2017. Retrieved 28 November 2017.
  22. ↑ Oplinger M, Andrews CO (January 2013). "Nitrofurantoin contraindication in patients with a creatinine clearance below 60 mL/min: looking for the evidence". The Annals of Pharmacotherapy. 47 (1): 106–111. doi:10.1345/aph.1R352. PMID   23341159. S2CID   28181644.
  23. ↑ American Geriatrics Society 2012 Beers Criteria Update Expert Panel (April 2012). "American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults". Journal of the American Geriatrics Society. 60 (4): 616–631. doi:10.1111/j.1532-5415.2012.03923.x. PMC   3571677 . PMID   22376048.{{cite journal}}: CS1 maint: numeric names: authors list (link)
  24. ↑ Jick SS, Jick H, Walker AM, Hunter JR (September 1989). "Hospitalizations for pulmonary reactions following nitrofurantoin use". Chest. 96 (3): 512–515. doi:10.1378/chest.96.3.512. PMID   2766810.
  25. 1 2 3 Huttner A, Verhaegh EM, Harbarth S, Muller AE, Theuretzbacher U, Mouton JW (September 2015). "Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials". The Journal of Antimicrobial Chemotherapy. 70 (9): 2456–2464. doi: 10.1093/jac/dkv147 . PMID   26066581.
  26. ↑ Williams EM, Triller DM (May 2006). "Recurrent acute nitrofurantoin-induced pulmonary toxicity". Pharmacotherapy. 26 (5): 713–718. doi:10.1592/phco.26.5.713. PMID   16718946. S2CID   29563196.
  27. ↑ Goemaere NN, Grijm K, van Hal PT, den Bakker MA (May 2008). "Nitrofurantoin-induced pulmonary fibrosis: a case report". Journal of Medical Case Reports. 2 (1): 169. doi: 10.1186/1752-1947-2-169 . PMC   2408600 . PMID   18495029.
  28. ↑ Amit G, Cohen P, Ackerman Z (March 2002). "Nitrofurantoin-induced chronic active hepatitis". The Israel Medical Association Journal. 4 (3): 184–186. PMID   11908259.
  29. ↑ Tan IL, Polydefkis MJ, Ebenezer GJ, Hauer P, McArthur JC (February 2012). "Peripheral nerve toxic effects of nitrofurantoin". Archives of Neurology. 69 (2): 265–268. doi: 10.1001/archneurol.2011.1120 . PMID   22332195.
  30. ↑ Conklin JD (1978). "The pharmacokinetics of nitrofurantoin and its related bioavailability". Pharmacokinetics. Antibiotics and Chemotherapy. Vol. 25. pp. 233–252. doi:10.1159/000401065. ISBN   978-3-8055-2752-1. PMID   352255.
  31. 1 2 3 Shah RR, Wade G (1989). "Reappraisal of the risk/benefit of nitrofurantoin: review of toxicity and efficacy". Adverse Drug Reactions and Acute Poisoning Reviews. 8 (4): 183–201. PMID   2694823.
  32. ↑ McCalla DR, Kaiser C, Green MH (January 1978). "Genetics of nitrofurazone resistance in Escherichia coli". Journal of Bacteriology. 133 (1): 10–16. doi:10.1128/JB.133.1.10-16.1978. PMC   221970 . PMID   338576.
  33. ↑ Bains A, Buna D, Hoag NA (2009). "A retrospective review assessing the efficacy and safety of nitrofurantoin in renal impairment". Canadian Pharmacists Journal. 142 (5): 248–252. doi:10.3821/1913-701X-142.5.248. S2CID   56795699.
  34. ↑ Blass B (24 April 2015). Basic Principles of Drug Discovery and Development. Elsevier. p. 513. ISBN   9780124115255.
  35. ↑ Tu Y, McCalla DR (August 1975). "Effect of activated nitrofurans on DNA". Biochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesis. 402 (2): 142–149. doi:10.1016/0005-2787(75)90032-5. PMID   1100114.
  36. ↑ "Nitrofurantoin". drugs.com. Archived from the original on 18 May 2015. Retrieved 2 May 2015.
  37. 1 2 "Joint FAO/WHO Technical Workshop on Residues of Veterinary Drugs without ADI/MRL - Bangkok, 24 – 26 August 2004". www.fao.org. Archived from the original on 4 December 2008.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.